Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030225 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
A Phase 2 study, sponsored by Vital Therapies.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00030225 is a Phase 2 study that has completed, run by Vital Therapies. The registered enrollment target is 19 participants.
The verdict
NCT00030225, a Phase 2 study, has completed, sponsored by Vital Therapies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.
Interventions
- BIOLOGICAL ELAD
- OTHER Standard of care (Control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030225
The ClinicalTrials.gov registry entry for NCT00030225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vital Therapies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ELAD is the first listed.
NCT00030225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030225 about?
NCT00030225 is a clinical study titled "Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure". The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.
What is the current status of trial NCT00030225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2002-01. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00030225?
The interventions under investigation include: ELAD (BIOLOGICAL), Standard of care (Control) (OTHER).
Who is sponsoring clinical trial NCT00030225?
This trial is sponsored by Vital Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.